Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: An open randomized cross-over study

Journal of Digestive Diseases

Volumn 13, Issue 2, 2012, Pages 113-119

  Du, Yi Qi ^a   Guo, Wen Yuan ^b   Zou, Duo Wu ^a   Zhan, Xian Bao ^a   Li, Zhen ^a   Hu, Jin Hong ^a   Gong, Yan Fang ^a   He, Jia ^c   Lu, Jian Ping ^a   Li, Zhao Shen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Ilaprazole; Pharmacodynamics; Proton pump inhibitor

Indexed keywords

CYTOCHROME P450 2C19; ILAPRAZOLE; OMEPRAZOLE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME POLYMORPHISM; FEMALE; HELICOBACTER INFECTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH PH;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; H(+)-K(+)-EXCHANGING ATPASE; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; POLYMORPHISM, GENETIC; REFERENCE VALUES; STOMACH; SULFOXIDES; YOUNG ADULT;

EID: 84862926025     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00557.x     Document Type: Article

References (21)

1. Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr Opin Pharmacol 2008; 8: 677-84.
2. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996; 38: 649-54.
3. Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet 2008; 47: 1-6.
4. Kil BJ, Kim IW, Shin CY etal. Comparison of IY81149 with omeprazole in rat reflux oesophagitis. J Auton Pharmacol 2000; 20: 291-6.
5. Periclou AP, Goldwater R, Lee SM etal. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther 2000; 68: 304-11.
6. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007; 8: 1199-210.
7. Hunfeld NG, Mathot RA, Touw DJ etal. Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 2008; 65: 752-60.
8. Schwab M, Klotz U, Hofmann U etal. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78: 627-34.
9. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2006; 80: 539-48.
10. Li Y, Zhang W, Guo D, Zhou G, Zhou H, Xiao Z. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta 2008; 391: 60-7.
11. Li ZS, Zhan XB, Xu GM, Chen NN, Liao Z. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial. J Gastroenterol Hepatol 2007; 22: 815-20.
12. Ho KY, Kuan A, Zaño F etal. Randomized, parallel, double-blind comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodenal ulcers. J Gastroenterol 2009; 44: 697-707.
13. Wang L, Zhou L, Lin S, Hu H, Xia J. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastroenterol 2011; 45: 322-9.
14. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23 (Suppl 2): 2-8.
15. Giannini EG, Savarino V, Testa R. Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease. Dig Dis Sci 2006; 51: 1602-6.
16. Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-7.
17. Yamagishi H, Koike T, Ohara S etal. Early effects of lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers. World J Gastroenterol 2008; 14: 2049-54.
18. Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 966-72.
19. Cho H, Choi MK, Cho DY etal. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol 2011. [Epub ahead of print]. DOI: 10.1177/0091270011408611.
20. Zhou G, Tan ZR, Zhang W etal. An improved LC-MS/MS method for quantitative determination of ilaprazole and its metabolites in human plasma and its application to a pharmacokinetic study. Acta Pharmacol Sin 2009; 30: 1330-6.
21. Zhou G, Shi S, Zhang W etal. Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments. Biomed Chromatogr 2010; 24: 1130-5.